1. Sankaranarayanan R, Thara S, Esmy PO, et al. Cervical cancer: screening and therapeutic perspectives. Medical Principles and Practice 2008;17(5):351-64. [
DOI:10.1159/000141498]
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer 2013;49(6):1374-403. [
DOI:10.1016/j.ejca.2012.12.027]
3. Khan SA, Thomas HC, Toledano MB, et al. p53 Mutations in human cholangiocarcinoma: a review. Liver international 2005; 25(4): 704-16. [
DOI:10.1111/j.1478-3231.2005.01106.x]
4. Gomez-Lazaro M, Fernandez-Gomez FJ, Jordan J. p53: twenty five years understanding the mechanism of genome protection. Journal of physiology and biochemistry 2004; 60(4):287-307. [
DOI:10.1007/BF03167075]
5. Pietsch E, Humbey O, Murphy M. Polymorphisms in the p53 pathway. Oncogene 2006; 25(11):1602-11. [
DOI:10.1038/sj.onc.1209367]
6. Murphy M. Polymorphic variants in the p53 pathway. Cell Death & Differentiation 2006;13(6):916-20. [
DOI:10.1038/sj.cdd.4401907]
7. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 16; 408(6810): 307-10. [
DOI:10.1038/35042675]
8. Karki R, Pandya D, Elston RC, et al. Defining "mutation" and "polymorphism" in the era of personal genomics. BMC Medical Genomics 2015; 8:37. [
DOI:10.1186/s12920-015-0115-z]
9. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000; 9(10):1037-42.
10. Noma C, Miyoshi Y, Taguchi T, et al. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer letters 2004; 210(2):197-203. [
DOI:10.1016/j.canlet.2004.03.031]
11. Pérez LO, Abba MC, Dulout FN, Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in LaPlata, Argentina. World J Gastroenterol 2006; 12(9):1426-9. [
DOI:10.3748/wjg.v12.i9.1426]
12. Trifa F, Karray-Chouayekh S, Mabrouk I, et al. Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer epidemiology 2010; 34(2): 184-8. [
DOI:10.1016/j.canep.2010.02.007]
13. Dumont P, Leu JI, Della Pietra AC, The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature genetics 2003; 33(3):357-65. [
DOI:10.1038/ng1093]
14. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007; 90: 1-6.
15. Ermel AC, Brown DR. Viral Infections. In: Kasper DL, Fauci AS, editors. Harrison's Infectious Diseases. 3rd ed. New York: The McGraw-Hill Companies, 2017, 768-73.
16. Miller S. Human Tumour Viruses. In: Carroll KC, Butel JS, Morse SA, Mietzner TA, editors. Jawetz, Melnick, & Adelberg's Medical Microbiology. 27th ed. New York: McGraw-Hill Education, 2016, 619-39.
17. Jones C. Cervical cancer: is herpes simplex virus type II a cofactor? Clinical microbiology reviews 1995; 8(4): 549-56. [
DOI:10.1128/CMR.8.4.549]
18. Alibek K, Baiken Y, Kakpenova A, et al. Implication of human herpesviruses in oncogenesis through immune evasion and supression. Infectious agents and cancer 2014; 9(3):1-8. [
DOI:10.1186/1750-9378-9-3]
19. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 1998; 393(6682):229-34. [
DOI:10.1038/30400]
20. Lattuada D, Vigano P, Somigliana E, et al. Analysis of the codon 72 polymorphism of the TP53 gene in patients with endometriosis. Molecular human reproduction 2004;10(9):651-4. [
DOI:10.1093/molehr/gah093]
21. Read SJ, Kurtz JB. Laboratory diagnosis of common viral infections of the central nervous system by using a single multiplex PCR screening assay. Journal of clinical microbiology 1999;37(5):1352-5. [
DOI:10.1128/JCM.37.5.1352-1355.1999]
22. Taherkhani R, Farshadpour F, Makvandi M, et al. Determination of Cytomegalovirus Prevalence and Glycoprotein B Genotypes Among Ulcerative Colitis Patients in Ahvaz, Iran. Jundishapur journal of microbiology 2015;8(2):e17458. [
DOI:10.5812/jjm.17458]
23. Beckman G, Birgander R, Själander A, et al. Is p53 polymorphism maintained by natural selection? Human heredity 1994;44(5):266-70. [
DOI:10.1159/000154228]
24. Omori S, Yoshida S, Kennedy SH, et al. Polymorphism at codon 72 of the p53 gene is not associated with endometriosis in a Japanese population. Journal of the Society for Gynecologic Investigation 2004;11(4):232-6. [
DOI:10.1016/j.jsgi.2003.11.004]
25. Pillai RM, Sreevidya S, Pollock BH, Polymorphism at codon 72 of p53, human papillomavirus, and cervical cancer in South India. Journal of cancer research and clinical oncology 2002;128(11):627-31. [
DOI:10.1007/s00432-002-0383-9]
26. Kouamou V, Chin'ombe N, Matimba A, Ket al. P53 Codon 72 Polymorphism and the Risk of Cervical Cancer in Zimbabwean Women. International Journal of TROPICAL DISEASE & Health 2016;15(3):1-6. [
DOI:10.9734/IJTDH/2016/24676]
27. Basyar R, Saleh AZ, Sastradinata I, et al. p53 Gene Codon 72 Polymorphisms among Cervical Carcinoma Patients. Indonesian Journal of Obstetrics and Gynecology 2015; 3(3):165-9. [
DOI:10.32771/inajog.v3i3.48]
28. Assoumou SZ, Boumba ALM, Ndjoyi-Mbiguino A, et al. The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women. Medical Oncology 2015;32(1):281. [
DOI:10.1007/s12032-014-0281-4]
29. Malisic E, Jankovic R, Brotto K, Radulovic S. TP53 codon 72 polymorphism and risk of cervical carcinoma in Serbian women. Archives of gynecology and obstetrics 2013; 288(3):621-5. [
DOI:10.1007/s00404-013-2783-2]
30. Li B, Wang X, Chen H, et al. TP53 codon 72 polymorphism and susceptibility to cervical cancer in the Chinese population: an update meta-analysis. International journal of clinical and experimental medicine 2015;8(6):9055-62.
31. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23: 3328-37. [
DOI:10.1038/sj.onc.1207428]
32. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. International journal of cancer 2004; 108(2): 196-9 [
DOI:10.1002/ijc.11548]
33. Bergamaschi D, Samuels Y, Sullivan A, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nature genetics 2006; 38(10):1133-41. [
DOI:10.1038/ng1879]
34. Shanehsazzadeh M, Sharifi-Rad J, Behbahani M, et al. Analysis of Human Papillomavirus and Herpes Simplex Virus Genus-2 from Patients with Cervical Cancer in Isfahan, Iran. Mater Sociomed 2014; 26(4): 234-6. [
DOI:10.5455/msm.2014.26.234-236]